Khorana, Alok A <br/><br/>
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.  [electronic resource] 

 -  The New England journal of medicine  02 2019 
 - 720-728 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1533-4406 
<br/><br/><label>Standard No.: </label>10.1056/NEJMoa1814630  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Double-Blind Method<br/>Factor Xa Inhibitors--adverse effects<br/>Female<br/>Hemorrhage--chemically induced<br/>Humans<br/>Incidence<br/>Intention to Treat Analysis<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Neoplasms--complications<br/>Risk Factors<br/>Rivaroxaban--adverse effects<br/>Treatment Outcome<br/>Venous Thromboembolism--etiology